newsfeedback@fool.com (Prosper Junior Bakiny)

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what’s transpired in 2025. Among them are CRISPR Therapeutics (CRSP 0.12%) and Merck (MRK -1.37%), […]

The recent stock market sell-off is dragging down many corporations, including Snap (SNAP 1.14%), a social media specialist. Though the company ended 2024 with strong momentum, its shares have declined by 18% since January. Still, there are good reasons to

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry’s hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss

It’s hard to argue with the kinds of results Eli Lilly (LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.

Everyone wants a piece of the artificial intelligence (AI) market. Since ChatGPT’s release, AI has grabbed countless headlines on Wall Street and helped many companies rise in prominence. There are many options for investors looking to cash in, and no

Dividend investing will likely never go out of style. This is not only because people generally like the idea of earning some money while doing nothing, but also because companies that consistently pay and increase their payouts usually have excellent

Every investor has heard the phrase “buy low, sell high.” It’s a simple enough piece of advice that’s less simple to apply. What exactly qualifies as “low”? One possible answer is when a company’s shares fall significantly in one day

What’s going on with CRISPR Therapeutics (CRSP 0.83%)? The company’s shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn’t recovered: The stock is down 23% year to

No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing for as long as possible — preferably forever.

Every company faces challenges. Sometimes, those issues are deeply damaging to a corporation’s investment thesis. Other times, though, that’s not the case, and the price drop represents a great buying opportunity for long-term investors. There are always companies in the